“Scientists have designed a new form of insulin that can automatically switch itself on and off depending on glucose levels in the blood. In animals, this ‘smart’ insulin reduced high blood-sugar concentrations effectively while preventing levels from dropping too low… A spokesperson for Novo Nordisk says that although this study is a proof of principle of NNC2215’s glucose-sensitive insulin properties, further research to optimize the molecule is ongoing.”

From the research article: “Here we report the design and properties of NNC2215, an insulin conjugate with bioactivity that is reversibly responsive to a glucose range relevant for diabetes, as demonstrated in vitro and in vivo… In animal studies, the glucose-sensitive bioactivity of NNC2215 was demonstrated to lead to protection against hypoglycaemia while partially covering glucose excursions.”

Brought to you by a passionate research group from Novo Nordisk, home of the $1,349 per month weight-loss drug Wegovy

This is still fairly early-stage research so the final commercialization might take quite some time

The article itself, open access: https://doi.org/10.1038/s41586-024-08042-3